Table IV.
Clinical Characteristics Recorded From Patient Files for Those With Single‐Infection for RSV, PIV‐3, Influenza A, hMPV, hBoV, hCoV‐NL63, and hoV‐OC43, and Rhinovirus, respectively
| RSVa (n = 60) | PIV‐3 (n = 25) | Influenza A (n = 7) | hMPV (n = 9) | hBoV (n = 9) | hCoV‐NL63 (n = 1) | hCoV‐OC43 (n = 3)b | hCoV‐229E (n = 1) | hRV (n = 109) | |
|---|---|---|---|---|---|---|---|---|---|
| Demographics | |||||||||
| Mean age (months) ± SD | 3.6 ± 2.5 | 5.9 ± 4.6 | 4.0 ± 3.5 | 6.5 ± 5.0 | 10.8 ± 7.9 | 3 months | 3.1 ± 1.9 | 1.6 months | 7.3 ± 10.5 |
| Sex (males %) | 61.7% | 64.0% | 42.9% | 66.7% | 66.7% | 0% | 33.3% | 100.0% | 60.5% |
| O2 supplementation | 38 (63.3%) | 14 (56.0%) | 3 (42.9%) | 6 (66.7%) | 6 (66.7%) | 1 (100%) | 2 (66.7%) | 1 (100%) | 58 (53.2%) |
| Malnourished (wasted) | 8 (13.3%) | 4 (16.0%) | 1 (14.3%) | 0 | 2 (22.2%) | 0 | 1 (33.3%) | 0 | 0 |
| Undernourished (stunted) | 4 (6.7%) | 0 | 0 | 1 (11.1%) | 2 (22.2%) | 0 | 0 | 0 | 0 |
| Unknown nutritional status | 17 (28.3%) | 2 (8.0%) | 0 | 2 (22.2%) | 2 (22.2%) | 1 (100%) | 1 (33.3%) | 1 (100%) | 3 (2.7%) |
| Clinical characteristics | |||||||||
| Respiratory distress | 38 (63.3%) | 14 (56.0%) | 3 (42.9%) | 6 (66.7%) | 6 (66.7%) | 1 (100%) | 2 (66.7%) | 1 (100%) | 58 (53.2%) |
| Crepitations | 29 (48.3%) | 16 (64.0%) | 3 (42.9%) | 6 (66.7%) | 1 (11.1%) | 0 | 1 (33.3%) | 1 (100%) | 43 (39.4%) |
| Wheezing | 13 (21.7%) | 9 (36.0%) | 1 (14.3%) | 3 (33.3%) | 3 (33.3%) | 1 (100%) | 1 (33.3%) | 0 | 28 (25.7%) |
| Lobar consolidation | 2 (3.3%) | 2 (8.0%) | 0 | 0 | 1 (11.1%) | 0 | 0 | 0 | 1 (0.1%) |
| GIT symptoms | 9 (15.0%) | 3 (12.0%) | 1 (14.3%) | 2 (22.2%) | 3 (33.3%) | 0 | 1 (33.3%) | 1 (100%) | 1 (0.1%) |
| Clinical diagnosis | |||||||||
| Upper respiratory tract infection | 1 (1.6%) | 0 | 1 (14.3%) | 0 | 2 (22.2%) | 0 | 0 | 0 | 5 (4.6%) |
| Lower respiratory tract infection | 47 (78.3%) | 25 (100%) | 5 (71.4%) | 8 (88.9%) | 7 (77.8%) | 1 (100%) | 2 (66.7%) | 1 (100%) | 79 (72.5%) |
| Bronchiolitis | 15 (25.0%) | 6 (24.0%) | 2 (28.6%) | 2 (22.2%) | 1 (11.1%) | 0 | 1 (33.3%) | 0 | 16 (14.7%) |
| Bronchopneumonia | 14 (23.3%) | 5 (20.0%) | 2 (28.6%) | 1 (11.1%) | 3 (33.3%) | 0 | 0 | 0 | 21 (19.3%) |
| Pneumonia | 17 (28.3%) | 14 (56.0%) | 1 (14.3%) | 2 (22.2%) | 1 (11.1%) | 1 (100%) | 0 | 0 | 30 (27.5%) |
| Bronchitis | 1 (1.6%) | 0 | 0 | 0 | 1 (11.1%) | 0 | 0 | 0 | 2 (1.8%) |
| LRTI not otherwise specified | 6 (10.0%) | 0 | 0 | 3 (33.3%) | 1 (11.1%) | 0 | 1 (33.3%) | 1 (100%) | 10 (9.2%) |
| Croup | 1 (1.6%) | 2 (8.0%) | 0 | 0 | 0 | 1 (100%) | 0 | 0 | 0 |
| Asthma exacerbation | 2 (3.3%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Apnea attacks | 7 (11.7%) | 3 (12.0%) | 0 | 0 | 0 | 0 | 1 (33.3%) | 1 (100%) | 5 (4.6%) |
a
Additional information for 60/67 of hospitalized and outpatients with RSV single infections as identified by real‐time RT‐PCR were included in this analysis.
b
Additional information could only be obtained for two hCoV‐OC43 infected patients.